Impact of Stereoselectivity on the Pharmacokinetics and Pharmacodynamics of Antiarrhythmic Drugs

[1]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.

[2]  P. Ho,et al.  Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers , 2000, European Journal of Clinical Pharmacology.

[3]  F. Belpaire,et al.  Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. , 2000, Journal of clinical psychopharmacology.

[4]  F. Gonzalez,et al.  Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[5]  J. Turgeon,et al.  Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings , 2000, Clinical pharmacology and therapeutics.

[6]  K. Hanada,et al.  Enantioselective Binding of Propranolol, Disopyramide, and Verapamil to Human α1‐Acid Glycoprotein , 2000 .

[7]  Yukihiro Kuroda,et al.  Enantioselective binding analysis of verapamil to plasma lipoproteins by capillary electrophoresis-frontal analysis. , 2000, Journal of chromatography. A.

[8]  D. Zhong,et al.  Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Y. Zhou,et al.  Fluoxetine impairs the CYP2D6‐mediated metabolism of propafenone enantiomers in healthy Chinese volunteers , 1999, Clinical pharmacology and therapeutics.

[10]  K. Korzekwa,et al.  Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. , 1999, British journal of clinical pharmacology.

[11]  W. Cai,et al.  The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. , 1999, British journal of clinical pharmacology.

[12]  J. Turgeon,et al.  Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. , 1999, Therapeutic drug monitoring.

[13]  U. Klotz,et al.  Stereoselective steady state disposition and action of propafenone in Chinese subjects. , 1998, British journal of clinical pharmacology.

[14]  K. Hanada,et al.  Enantioselective Tissue Distribution of the Basic Drugs Disopyramide, Flecainide and Verapamil in Rats: Role of Plasma Protein and Tissue Phosphatidylserine Binding , 1998, Pharmaceutical Research.

[15]  H Lennernäs,et al.  The Absence of Stereoselective P‐Glycoprotein‐mediated Transport of R/S‐Verapamil Across the Rat Jejunum , 1998, The Journal of pharmacy and pharmacology.

[16]  K. Stringer,et al.  Pharmacokinetics of Pirmenol Enantiomers and Pharmacodynamics of Pirmenol Racemate in Patients with Premature Ventricular Contractions , 1997, Journal of clinical pharmacology.

[17]  H. Blume,et al.  Enantioselective determination of diprafenone in human plasma. , 1997, Die Pharmazie.

[18]  A. Urae,et al.  No Effect of High‐Protein Food on the Stereoselective Bioavailability and Pharmacokinetics of Verapamil , 1996, Journal of clinical pharmacology.

[19]  B. Testa,et al.  Stereochemical Aspects of Drug Action and Disposition , 1996, Handbook of Experimental Pharmacology.

[20]  R. Mehvar,et al.  Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding. , 1996, Biopharmaceutics & drug disposition.

[21]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption 1 PII of original artic , 1996 .

[22]  G Ecker,et al.  Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. , 1996, Molecular pharmacology.

[23]  G. Lentini,et al.  Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  R. Lewanczuk,et al.  Pharmacokinetics of Verapamil and Norverapamil Enantiomers After Administration of Immediate and Controlled‐Release Formulations to Humans: Evidence Suggesting Input‐Rate Determined Stereoselectivity , 1995, Journal of clinical pharmacology.

[25]  C. Kerr,et al.  Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  J. Longstreth,et al.  The Effect of Food, Time of Dosing, and Body Position on the Pharmacokinetics and Pharmacodynamics of Verapamil and Norverapamil , 1995, Journal of clinical pharmacology.

[27]  J. Longstreth,et al.  Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. , 1995, British journal of clinical pharmacology.

[28]  A. Karim,et al.  Verapamil stereoisomerism: Enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both , 1995, Clinical pharmacology and therapeutics.

[29]  R. Mehvar,et al.  Input rate-dependent stereoselective pharmacokinetics. Experimental evidence in verapamil-infused isolated rat livers. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[30]  W. S. Akers,et al.  Influence of metabolites on protein binding of verapamil enantiomers. , 1995, British journal of clinical pharmacology.

[31]  M. Dhont,et al.  Protein binding of propranolol and verapamil enantiomers in maternal and foetal serum. , 1995, British journal of clinical pharmacology.

[32]  J. Schwartz,et al.  Verapamil stereoisomers during racemic verapamil administration: Effects of aging and comparisons to administration of individual stereoisomers , 1994, Clinical pharmacology and therapeutics.

[33]  J. Schwartz,et al.  Aging of women alters S‐verapamil pharmacokinetics and pharmacodynamics , 1994, Clinical pharmacology and therapeutics.

[34]  M. Fromm,et al.  An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. , 1994, Circulation.

[35]  T. Ishizaki,et al.  Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes. , 1994, The Journal of pharmacology and experimental therapeutics.

[36]  K. Kowalski,et al.  Absorption and Disposition of a New Antiarrhythmic Agent Bidisomide in Man , 1993, Pharmaceutical Research.

[37]  M. Eichelbaum,et al.  Identification of P450 enzymes involved in metabolism of verapamil in humans , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  J. Turgeon,et al.  Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. , 1993, The Journal of pharmacology and experimental therapeutics.

[39]  D. Abernethy,et al.  Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. , 1993, The Journal of pharmacology and experimental therapeutics.

[40]  D. Verotta,et al.  Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. , 1993, The Journal of pharmacology and experimental therapeutics.

[41]  C. Libersa,et al.  Stereoselective Hydroxylation of Mexiletine in Human Liver Microsomes: Implication of P450IID6− A Preliminary Report , 1993, Journal of cardiovascular pharmacology.

[42]  R. Mehvar.  Input rate‐dependent stereoselective pharmacokinetics: Enantiomeric oral bioavailability and blood concentration ratios after constant oral input , 1992, Biopharmaceutics & drug disposition.

[43]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[44]  D. Roden,et al.  Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. , 1992, British journal of clinical pharmacology.

[45]  K. Chiba,et al.  Stereoselective disposition and metabolism of disopyramide in pediatric patients. , 1991, The Journal of pharmacology and experimental therapeutics.

[46]  J. Turgeon,et al.  Resolution and Electrophysiological Effects of Mexiletine Enantiomers , 1991, The Journal of pharmacy and pharmacology.

[47]  H. Ogata,et al.  Comparative pharmacokinetics of unbound disopyramide enantiomers following oral administration of racemic disopyramide in humans. , 1991, Journal of pharmaceutical sciences.

[48]  M. Eichelbaum,et al.  Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. , 1991, Molecular pharmacology.

[49]  T. Ramsing,et al.  Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. , 1991, British journal of clinical pharmacology.

[50]  D. Roden,et al.  Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers , 1991, Clinical pharmacology and therapeutics.

[51]  R. Mehvar.  Apparent stereoselectivity in propafenone uptake by human and rat erythrocytes , 1991, Biopharmaceutics & drug disposition.

[52]  J. Ruppersberg,et al.  Stereoselective interaction of tocainide and its chiral analogs with the sodium channels in human myoballs , 1991, Pflügers Archiv.

[53]  W. Lindner,et al.  The effects of the stereoisomers of propafenone and diprafenone in guinea‐pig heart , 1991, British journal of pharmacology.

[54]  U. Klotz,et al.  Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. , 1990, The Journal of pharmacology and experimental therapeutics.

[55]  O. Gyllenhaal,et al.  Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. , 1990, Biopharmaceutics & drug disposition.

[56]  M. Piascik,et al.  Stereoselective and nonstereoselective inhibition exhibited by the enantiomers of verapamil. , 1990, Canadian journal of physiology and pharmacology.

[57]  A. S. Gross,et al.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. , 1989, British journal of clinical pharmacology.

[58]  F. Jamali,et al.  Enantioselective aspects of drug action and disposition: therapeutic pitfalls. , 1989, Journal of pharmaceutical sciences.

[59]  D. Roden,et al.  Stereoselective disposition and pharmacologic activity of propafenone enantiomers. , 1989, Circulation.

[60]  T. Kronbach,et al.  In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone , 1989, Clinical pharmacology and therapeutics.

[61]  M. Eichelbaum,et al.  Stereoselective protein binding of verapamil enantiomers. , 1988, Biochemical pharmacology.

[62]  R. Le Verge,et al.  Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[63]  M. Hollmann,et al.  Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. , 1988, Methods and findings in experimental and clinical pharmacology.

[64]  W. L. Nelson,et al.  Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[65]  D. Roden,et al.  Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. , 1988, Circulation.

[66]  W. D. Mason,et al.  Food increases the bioavailability of propafenone. , 1987, British journal of clinical pharmacology.

[67]  H. Boudoulas,et al.  Stereoselective Effects of Disopyramide Enantiomers in Humans , 1987, Journal of cardiovascular pharmacology.

[68]  C. Kerr,et al.  Stereoselective serum protein binding of mexiletine enantiomers in man. , 1987, Research communications in chemical pathology and pharmacology.

[69]  J. Turgeon,et al.  Stereoselective disposition of mexiletine in man. , 1986, British journal of clinical pharmacology.

[70]  W. Hillis,et al.  The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. , 1986, British journal of clinical pharmacology.

[71]  J. R. Schmid,et al.  Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers. , 1986, Journal of medicinal chemistry.

[72]  H. Boudoulas,et al.  Stereoselective pharmacokinetics of disopyramide enantiomers in man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[73]  M. Eichelbaum,et al.  Effects of d,l‐verapamil on atrioventricular conduction in relation to its stereoselective first‐pass metabolism , 1985, Clinical pharmacology and therapeutics.

[74]  H. Glossmann,et al.  Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart , 1985, British journal of pharmacology.

[75]  M. Eichelbaum,et al.  The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. , 1985, American heart journal.

[76]  M. Eichelbaum,et al.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. , 1984, British journal of clinical pharmacology.

[77]  M. Eichelbaum,et al.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. , 1984, British journal of clinical pharmacology.

[78]  C. Kerr,et al.  Stereospecific salivary excretion of tocainide enantiomers in man. , 1984, Research communications in chemical pathology and pharmacology.

[79]  G. Tucker,et al.  Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers , 1983, Clinical pharmacology and therapeutics.

[80]  A. Sedman,et al.  Serum binding of tocainide and its enantiomers in human subjects. , 1982, Research communications in chemical pathology and pharmacology.

[81]  R. Dahlqvist,et al.  Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man , 2004, European Journal of Clinical Pharmacology.

[82]  C. Kerr,et al.  Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[83]  M. Eichelbaum,et al.  Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines , 2004, European Journal of Clinical Pharmacology.

[84]  E. Mutschler,et al.  Single- and multiple-dose pharmacokinetics of R-(−)- and S-(+)-prenylamine in man , 2004, European Journal of Clinical Pharmacology.

[85]  R. Mehvar.  Input rate-dependent stereoselective pharmacokinetics: effect of pulsatile oral input. , 1994, Chirality.

[86]  R. Matucci,et al.  Stereoselectivity in central analgesic action of tocainide and its analogs. , 1993, Chirality.

[87]  P. Beaune,et al.  Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. , 1993, Molecular pharmacology.

[88]  A. Guillouzo,et al.  In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data. , 1991, Chirality.

[89]  G. Beatch,et al.  Tissue distribution of mexiletine enantiomers in rats. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[90]  G. Tucker,et al.  Enantiomer specific pharmacokinetics. , 1990, Pharmacology & therapeutics.

[91]  C. Kerr,et al.  The pharmacokinetics of the enantiomers of mexiletine in humans. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[92]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[93]  T. Moyer,et al.  Serum tocainide enantiomer concentrations in human subjects. , 1984, British journal of clinical pharmacology.

[94]  F. Follath,et al.  Reliability of Antiarrhythmic Drug Plasma Concentration Monitoring , 1983, Clinical pharmacokinetics.

[95]  Bernard,et al.  Advances in Drug Research , 1964 .